Eidos Therapeutics

30 articles about Eidos Therapeutics

• BridgeBio Pharma, Inc. Announces Completion of Merger with Eidos Therapeutics, Inc.

  1/26/2021

  BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) today announced that it has completed its acquisition of all of the outstanding shares of Eidos Therapeutics, Inc. (“Eidos”) (formerly Nasdaq: EIDX) common stock that BridgeBio did not already own.

• Eidos Therapeutics Reports Third Quarter 2020 Financial Results and Business Update

  10/29/2020

  Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today reported its financial results for the third quarter ended September 30, 2020 and provided an update on the company’s operations. “The completion of enrollment in our Phase 3 ATTRibute-CM clinical study marks the next milestone in the accelerated development of acoramidis for patients with transthyretin (TTR) amyloidosis (ATTR),” said Neil Kumar, PhD, chief executive officer of Eidos. “Sinc

• BridgeBio Pharma and Eidos Therapeutics Announce Merger Agreement

  10/5/2020

  Agreement Brings BridgeBio’s Clinical Development and Commercial Development Infrastructureto Bear Upon Eidos’Acoramidis, Creating Anticipated Value for Patients with ATTR and Investors

• 

  BridgeBio Acquires Remaining Stake in Eidos to Tune of $175 Million

  10/5/2020

  The transaction between BridgeBio and Eidos is expected to close in the first quarter of 2021.
• 

  BioSpace Movers & Shakers, Aug. 14

  8/14/2020

  Biopharma and life sciences companies bolster their executive ranks and boards with these Movers & Shakers.

• Eidos Therapeutics Appoints Industry Leaders With Significant Development and Commercial Expertise to Board of Directors

  8/7/2020

  Eidos Therapeutics, Inc. (Nasdaq: EIDX), a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin (TTR) amyloidosis (ATTR), today announced that it has added two new independent directors to its board who bring deep commercial and strategic experience to the company: Suzanne Sawochka Hooper, the former executive vice president and general counsel of Jazz Pharmaceuticals

• Eidos Therapeutics Reports Second Quarter 2020 Financial Results and Business Update

  8/6/2020

  Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the second quarter ended June 30, 2020 and provided an update on the company’s operations.

• Eidos Therapeutics Reports First Quarter 2020 Financial Results and Business Update

  5/8/2020

  Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX),  today reported its financial results for the first quarter ended March 31, 2020 and provided an update on the company’s operations.

• Eidos Therapeutics Reports Fourth Quarter and Year-End 2019 Financial Results and Business Update

  2/26/2020

  Eidos Therapeutics, Inc., reported its financial results for the fourth quarter and full year ended December 31, 2019 and provided an update on the company’s recent achievements.

• BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences

  2/22/2020

  BridgeBio Pharma, Inc., together with affiliate company Eidos Therapeutics announced that they are presenting at two upcoming investor conferences

• CORRECTION: BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

  11/16/2019

  AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

• BridgeBio and Eidos Present Data from Phase 2 Open Label Extension Suggesting Long-term Tolerability of AG10 and Stabilization of Transthyretin Amyloid Cardiomyopathy Disease Measures

  11/16/2019

  AG10 was Well Tolerated with Median 65 Weeks Follow-up since Phase 2 Initiation

• Eidos Therapeutics Reports Third Quarter 2019 Financial Results and Business Update

  10/31/2019

  Eidos Therapeutics, Inc. (Eidos) (Nasdaq: EIDX), a subsidiary of BridgeBio Pharma, Inc. (BridgeBio) (Nasdaq:BBIO), today reported its financial results for the third quarter ended September 30, 2019 and provided an update on the company’s recent achievements, upcoming events and chief financial officer transition plan.

• BridgeBio Pharma Terminates Merger Process With Its Subsidiary Eidos Therapeutics

  10/14/2019

  BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, announced today that it was unable to come to an agreement with the Special Committee formed by its subsidiary Eidos Therapeutics (NASDAQ

• Eidos Therapeutics Special Committee Rejects Proposal from BridgeBio Pharma to Acquire Shares

  9/12/2019

  Eidos Therapeutics, Inc. announced that the Special Committee of its Board of Directors unanimously rejected the non-binding proposal dated August 8, 2019 from BridgeBio Pharma, Inc., the parent entity of the Company’s majority stockholder, to purchase all of the outstanding common stock of the Company not already owned by BridgeBio for a fixed exchange ratio of 1.30 shares of BridgeBio common stock for each share of Eidos common stock.

• Eidos Therapeutics Confirms Receipt of Non-Binding Proposal from BridgeBio Pharma to Acquire Shares

  8/12/2019

  Forms Special Committee of Independent and Disinterested Directors to Review Proposal Advises Stockholders Take No Action at this Time

• EIDOS THERAPEUTICS INITIATES ATTRIBUTE-CM, A PHASE 3 STUDY OF AG10 IN ATTR-CM WITH REGISTRATIONAL 12-MONTH ENDPOINT

  2/27/2019

  Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX), today announced the initiation and design of its pivotal global Phase 3 trial (ATTRibute-CM) of AG10 in patients with transthyretin (TTR) amyloid cardiomyopathy (ATTR-CM).

• Eidos Therapeutics Announces Positive Phase 2 Data for AG10 in Symptomatic Patients with Mutant or Wild-Type TTR Amyloid Cardiomyopathy

  11/10/2018

  AG10 Was Well Tolerated in Subjects Administered 400 mg or 800 mg Twice Daily for 28 Days

• FDA Grants Orphan Drug Designation to Eidos Therapeutics’ Product Candidate, AG10, for Treatment of Transthyretin Amyloidosis

  10/3/2018

  The company plans to initiate Phase 3 studies in each indication in the first half of 2019.

• EIDOS THERAPEUTICS ANNOUNCES PUBLICATION OF AG10 MOLECULAR DESIGN IN JOURNAL OF MEDICINAL CHEMISTRY

  8/23/2018

  Eidos Therapeutics, Inc. (Eidos) (Nasdaq:EIDX) today announced publication of the design and preclinical characterization of its lead product candidate, AG10, in the Journal of Medicinal Chemistry.